Affordable Access

deepdyve-link
Publisher Website

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

Authors
  • Ikeda, Masafumi
  • Shiina, Shuichiro
  • Nakachi, Kohei
  • Mitsunaga, Shuichi
  • Shimizu, Satoshi
  • Kojima, Yasushi
  • Ueno, Hideki
  • Morizane, Chigusa
  • Kondo, Shunsuke
  • Sakamoto, Yasunari
  • Asaoka, Yoshinari
  • Tateishi, Ryosuke
  • Koike, Kazuhiko
  • Arioka, Hitoshi
  • Okusaka, Takuji
Type
Published Article
Journal
Investigational New Drugs
Publisher
Springer-Verlag
Publication Date
Oct 01, 2014
Volume
32
Issue
5
Pages
928–936
Identifiers
DOI: 10.1007/s10637-014-0109-2
PMID: 24829073
Source
Medline
License
Unknown

Abstract

The recommended dose for advanced HCC should be 400 mg/day TSU-68 and 100 mg/day S-1 for 4 weeks followed by 2-week rest.

Report this publication

Statistics

Seen <100 times